AXIM BiotechnologiesAXIM EBIT per Share is $0.00 as of Jun. 2025. The stock has 7 warning signs investors should review. Among 1,184 Biotechnology companies, AXIM Biotechnologies ranks better than 88.43% on this metric.
AXIM Biotechnologies's EBIT per Share for the
three
months ended in Jun. 2025 was $0.00.
Its EBIT per Share for the trailing twelve months (TTM) ended in Jun. 2025 was $0.00.
During the past 3 years, the average EBIT per Share Growth Rate was 53.30% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 35.80% per year.
During the past 10 years, the average EBIT per Share Growth Rate was 17.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for AXIM Biotechnologies's EBIT per Share or its related term are showing as below:
AXIM'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -255.7 Med: 17.6 Max: 53.3
Current: 53.3
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of AXIM Biotechnologies was 53.30% per year. The lowest was -255.70% per year. And the median was 17.60% per year.
AXIM's 3-Year EBIT Growth Rate is ranked better than 88.43% of 1184
companies
in the Biotechnology industry
Industry Median: 15.45
vs AXIM: 53.30
AXIM Biotechnologies (OTCPK:AXIM) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
AXIM Biotechnologies EBIT per Share Related Terms
AXIM Biotechnologies EBIT per Share Historical Data
* Premium members only.
The historical data trend for AXIM Biotechnologies's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Jun. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AXIM Biotechnologies (AXIM) has a EBIT per Share of $0.00 as of Jun. 2025. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on AXIM Biotechnologies and its competitors. According to the industry distribution chart, AXIM Biotechnologies ranks #137 out of 1184 companies in the Biotechnology industry, placing it in the top 11.6%.
Is AXIM Biotechnologies' EBIT per Share too high?
AXIM Biotechnologies' current EBIT per Share is $0.00. Based on the distribution chart, AXIM Biotechnologies ranks #137 out of 1184 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers.
How does AXIM Biotechnologies' EBIT per Share compare to HEPA and SCNI?
According to the Biotechnology industry distribution chart, AXIM Biotechnologies ranks #137 out of 1184 companies for EBIT per Share. This places AXIM Biotechnologies in the top 12% of its industry — outperforming the majority of peers. The industry median EBIT per Share is 15.45. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Biotechnology company?
The median EBIT per Share among Biotechnology companies is 15.45, based on 1,184 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on AXIM Biotechnologies and its competitors. For the Biotechnology industry, the median EBIT per Share is 15.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. AXIM Biotechnologies's current EBIT per Share is $0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AXIM Biotechnologies stock overvalued right now?
AXIM Biotechnologies (AXIM) has a current EBIT per Share of $0.00. The current EBIT per Share is $0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For AXIM Biotechnologies (AXIM), the current EBIT per Share is $0.00 as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
AXIM Biotechnologies Inc is a integrated research and development company and developer of diagnostic healthcare solutions serving to enhance the health of people. The company focuses on improving the landscape for the diagnosis of ophthalmological conditions such as Dry Eye Disease through rapid diagnostic tests. Additionally, The company owns IP and has conducted research on SARS-CoV-2 (COVID-19) rapid neutralizing antibody tests to detect levels of functional neutralizing antibodies that are believed to prevent SARS-CoV-2 from entering the host cells.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AXIM has been successfully added to your 